CClinicalTrials.gg
Sign In
TerminatedNCT04268823Updated Jun 20, 2024Results posted

Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of QBW251 and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Terminated at 12 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by Novartis Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision
Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

The purpose of this study was to determine whether potentiating the cystic fibrosis transmembrane conductance regulator (CFTR) with QBW251 in subjects with COPD would be efficacious with regards to reducing lung and systemic inflammation and bacterial colonization as potential drivers of airway obstruction, airway destruction, remodeling and exacerbations.

Furthermore, this study provided supportive data to investigate the relationship of COPD phenotype and the response in small airway structure, function, mucus load and spirometry indices as well as in improvement of overall COPD symptoms and quality of life.

Read the detailed description

This was a randomized, subject and investigator blinded, parallel-group, placebo controlled study investigating the mode of action (MoA) and preliminary efficacy and safety of QBW251 administered orally twice daily (b.i.d.) for 12 weeks in subjects with moderate to severe COPD (GOLD 2-3).

The study consisted of the following periods: Screening, Baseline / Day 1, Treatment , and End of the Study followed by an additional post-treatment safety phone call. The total duration for each subject in the study is up to approximately 18 weeks.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease
03

In context

Lung Diseases

3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.

This study's enrollment of 54 is below the median of 72 across 2,118 interventional studies indexed under Lung Diseases.

Browse Lung Diseases studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 228 are open to participants now.

Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients who have signed an Informed Consent Form prior to initiation of any study-related procedure.
  2. Male and female adults aged ≥40 years at screening.

  3. Patients with stable COPD, stages GOLD 2-3, according to the current GOLD strategy (GOLD 2019) at screening.

    Patients with a post-bronchodilator FEV1/FVC \< 0.70 at screening

  4. Patients with airflow limitation indicated by a post-bronchodilator FEV1 ≥ 30% and FEV1 \< 80% of the predicted normal at Screening who must have had at least 2 documented moderate or at least 1 documented severe exacerbation(s) between January 2019 to study screening.
  5. Patients with sputum positive (>0 CFU) for at least one strain of potentially pathogenic microorganism at screening (H influenzae, H parainfluenzae, P aeruginosa, S pneumoniae, S aureus, Moraxella catarrhalis, Enterobacteriaceae, Stenotrophomonas maltophilia, Burkholderia species, and Achromobacter species or any potential pathogenic bacteria measured by dilution/outgrowth. Any organism that is to be included and that is not included in the list of the protocol defined pathogens will be discussed case by case). Sputum samples may be re collected and re-tested once during the screening period.

  6. Patients who have been treated with a combination of LABA/LAMA or LABA/ICS or LABA/LAMA/ICS at a stable dose for the last 3 months prior to screening.

    COPD patients are allowed to stay on macrolides as background therapy if they have bronchiectasis as a secondary diagnosis and if they are treated with them at a stable dose 3 months before screening.

  7. Patients with plasma fibrinogen level ≥ 320 mg/dL at screening. Fibrinogen may be re-tested once during the screening period.
  8. A COPD Assessment Test (CAT) score of at least 10 at screening.
  9. Current or ex-smokers who have a smoking history of at least 10 pack years (e.g. 10 pack years = 1 pack/day x 10 years, or 0.5 pack/day x 20 years) at screening.
  10. Patients featuring chronic bronchitis, defined as productive cough that occurs on most days (defined as >50% of days) during at least 3 consecutive months in the year prior to screening, as assessed by documentation of patient recollection (anamnesis) or documented in patients' records.
  11. Able to communicate well with the investigator, to understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of long-QT syndrome or whose QTcF interval at screening (Fridericia method) is prolonged (QTcF >450 ms in males, >460 ms in females).
  2. Patients who have a clinically significant* ECG abnormality before randomization. Note: Clinically significant abnormalities may include but are not limited to the following: left bundle branch block, Wolff-Parkinson-White syndrome, clinically significant arrhythmias (e.g., atrial fibrillation, ventricular tachycardia).
  3. Clinical laboratory values abnormalities (including Gamma GT, AST, ALT, total bilirubin or creatinine) considered as clinically significant in the opinion of the Investigator at screening. For additional guidance on hepatic parameters see exclusion criterion #5.
  4. Patients who have clinically significant renal, cardiovascular (such as but not limited to unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, myocardial infarction), neurological, endocrine, immunological, psychiatric, gastrointestinal, or hematological abnormalities, which could interfere with the assessment of the efficacy and safety of the study treatment, or patients with uncontrolled Type II diabetes.

  5. Patients with a history or current treatment for hepatic disease including but not limited to acute hepatitis, cirrhosis or hepatic failure.

    • Patients with stable chronic hepatitis may be included in the study by agreement with Novartis Medical Expert on a case-by-case basis.
    • A history of resolved Hepatitis A is not exclusionary.
    • Patients with prothrombin time international normalized ratio (PT/INR) of more than 1.5xULN at screening. Patients excluded for the PT/INR of more than 1.5xULN can be re-screened when the values have returned to normal.
  6. Patients with a history of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin. Patients with a history of cancer and 5 years or more disease free survival time may be included in the study by agreement with Novartis Medical Monitor on a case-by-case basis.
  7. Patients who develop a COPD exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization during screening. Re-screening is permitted after a minimum of 2 weeks after the resolution of the COPD exacerbation (i.e 2 weeks after the stop of SOC therapy for exacerbation).
  8. Patients who have had a respiratory tract infection within 4 weeks prior to screening. If a respiratory tract infection occurs during screening, patients can be re-screened after a minimum of 2 weeks after resolution of the respiratory tract infection.
  9. Patients with history of asthma or any other clinically relevant lung diseases..

  10. Patients with suspected active pulmonary tuberculosis or currently being treatment for active pulmonary tuberculosis.

    Note: Patients with a history of pulmonary tuberculosis can be enrolled if they meet the following requirements: history of appropriate drug treatment followed by negative imaging results within 12 months prior to screening suggesting low probability of recurrent active tuberculosis.

  11. Patients with pulmonary lobectomy, lung volume reduction surgery, bronchoscopic lung volume reductions, or lung transplantation.
  12. Patients participating in or planning to participate in the active phase of a supervised pulmonary rehabilitation program during the trial. Participation in a maintenance program is permitted. Note: the supervised pulmonary rehabilitation program as a maintenance program has to be ongoing for at least 3 months at the time of enrollment.
  13. Patients with a body mass index (BMI) of more than 40 kg/m2.
  14. Patients receiving any medications in the classes listed in Table 6-5.
  15. Patients receiving any COPD related medications in the classes specified in Table 6-6, unless they undergo the required washout period prior to screening and follow the adjustment to treatment program.
  16. Patients receiving medications in the classes listed in Table 6-2 should be excluded unless the medication has been stabilized for the specified period and the stated conditions have been met.
  17. Use of other investigational drugs (approved or unapproved) within 30 days or 5 half-lives prior to screening, or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations.
  18. Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.
  19. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using acceptable effective methods of contraception during study participation.
  20. Patients who have not achieved an acceptable spirometry result at screening in accordance with American Thoracic Society (ATS)/ European Respiratory Society (ERS) criteria for acceptability and repeatability.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    QBW251

    Oral use, one capsule twice daily.

    Drug: QBW251

  • Placebo comparator
    Placebo

    Oral use, one capsule twice daily.

    Drug: Placebo

Interventions

  • DrugQBW251

    Capsule 300mg

  • DrugPlacebo

    Capsule 300mg

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Fibrinogen Plasma Concentrations After 12 Weeks of Treatment

    To assess the effect of QBW251 compared to placebo after 12 weeks of treatment on fibrinogen. The least-squares means for change from baseline in fibrinogen plasma concentrations after 12 weeks visits for each individual dose group were obtained from a linear mixed effects model for repeated measures (MMRM). A MMRM was fitted to the changes from baseline in fibrinogen for all time points until Day 84. A decrease in fibrinogen plasma concentration indicates improvement.

    Time frame: Baseline, week 12.

Secondary outcomes

  1. Change From Baseline in Total Bacteria Load of log10 Colony Forming Units (CFU) After 12 Weeks of Treatment

    Change from baseline in total bacteria load of colony forming units of potentially pathogenic microorganisms in sputum. A decrease in airway bacterial colonization as detected in the sputum is considered improvement.

    Time frame: Baseline, week 12.

  2. Change From Baseline in COPD Assessment Test (CAT) Questionnaire After 12 Weeks of Treatment

    The COPD assessment test (CAT) is a short instrument which was used to quantify the symptom burden of COPD and disease severity of participants in this study. The CAT consists of 8 items, each presented as a semantic 6-point differential scale (0-5), providing a total range from 0 to 40. A higher score indicates a worse health status.

    Time frame: Baseline, week 12.

  3. Change From Baseline in Euro Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire After 12 Weeks of Treatment

    The EQ-5D-3L questionnaire is a general health status and health utility measure which captures 5 dimensions of health state: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and visual analog has a scale 0 to 100 (0=worst imaginable health state, 100=best imaginable health state).

    Time frame: Baseline, week 12.

  4. Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total and Domain Scores After 12 Weeks of Treatment

    The St. George's Respiratory questionnaire (SGRQ) was used to provide the health status measurements. The SGRQ contains 50 items divided into two parts covering three aspects of health related to COPD: Part I covers "Symptoms", Part II covers "Activity" and "Impacts". A score is calculated for each of these three subscales including the "Total" score. In each case the lowest possible value is zero and the highest 100. Higher values correspond to greater impairment of health status.

    Time frame: Baseline, week 12.

  5. Change From Baseline in Cough and Sputum Assessment Questionnaire (CASA-Q) After 12 Weeks of Treatment

    The CASA-Q is a validated questionnaire used to measure cough and sputum production, and their impact in patients with COPD and/or chronic bronchitis. There are only domain scores and no overall score. The scores in each domain range from 0 to 100, with lower scores indicating more severe symptoms or a higher impact.

    Time frame: Baseline, week 12.

  6. Pre-dose Trough Concentration (Ctrough) of QBW251

    Pharmacokinetic blood samples were collected and evaluated in all participants exposed to QBW251. QBW251 was analyzed by a validated Liquid Chromatography with tandem Mass Spectrometry. Concentration below the lower limit of quantification (LLOQ) was reported as zero.

    Time frame: Day 1, Day 28, Day 56 and Day 84

  7. Change From Baseline in Trough FEV1 After 12 Weeks of Treatment

    FEV1 (forced expiratory volume in one second) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The least-squares means for change from baseline in FEV1 to assess the effect of QBW251 compared to placebo after 12 weeks were obtained from a linear mixed effects model for repeated measures (MMRM). A positive change from baseline in pre-dose FEV1 is considered a favourable outcome.

    Time frame: Baseline, week 12.

  8. Change From Baseline in FVC After 12 Weeks of Treatment

    To assess the effect of QBW251 compared to placebo after 12 weeks of treatment on spirometry (Forced Vital Capacity). Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.

    Time frame: Baseline, week 12

  9. Change From Baseline in FEV1/FVC After 12 Weeks of Treatment

    To assess the effect of QBW251 compared to placebo after 12 weeks of treatment on spirometry. FEV1/FVC is the percent of a person's vital capacity that they are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC).

    Time frame: Baseline, week 12.

  10. Maximum Observed Plasma Concentrations (Cmax) of QBW251 in a Subset of Patient Population

    Cmax is the maximum (peak) observed plasma concentration of QBW251 after dose administration. QBW251 was analyzed by a validated Liquid Chromatography with tandem Mass Spectrometry. Concentration below the lower limit of quantification was reported as zero. Serial plasma PK concentrations were sampled on Day 1 and Day 28 up to 8 hours post dose in a subset of the patient population.

    Time frame: Pre dose, Post dose (1, 2, 3, 4, 6, and 8 hours) at Day 1 and Day 28.

  11. Maximum Observed Plasma Concentrations (Cmax) of QBW251

    Cmax is the maximum (peak) observed plasma concentration of QBW251 after dose administration. QBW251 was analyzed by a validated Liquid Chromatography with tandem Mass Spectrometry. Concentration below the lower limit of quantification was reported as zero. On Day 56 and Day 84 pre-dose and 3 hour post dose sparse samples were collected from all participants.

    Time frame: Post-dose (3 hours) at Day 56 and Day 84.

  12. Area Under Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) of QBW251

    Pharmacokinetic blood samples were collected and evaluated in all participants exposed to QBW251. QBW251 was analyzed by a validated Liquid Chromatography with tandem Mass Spectrometry. Concentration below the lower limit of quantification was reported as zero. AUClast is the area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (tlast) of QBW251.

    Time frame: Pre dose, Post dose (1, 2, 3, 4, 6, and 8 hours) at Day 1 and Day 28

  13. On-treatment Analysis of Time to First COPD Exacerbation Using Cox Regression Model

    To assess the effect of QBW251 compared to placebo after 12 weeks of treatment on COPD exacerbations, exacerbations defined by EXACT-PRO questionnaire. The protocol defined that the time-to-event analyses were to be carried out only upon sufficient number of exacerbation events occur during the study to estimate the median in either of the treatment groups.

    Time frame: Baseline, week 12.

  14. Proportion of Patients (Percentage) With Exacerbations

    The EXACT-PRO is a validated 14-item electronic questionnaire designed to detect the frequency, severity, and duration of exacerbations in participants with COPD. Minimum score is 0 and Maximum score is 40 (higher scores indicate worsening indicative of an exacerbation). EXACT-PRO-defined exacerbations are defined as a persistent increase from baseline in total EXACT-PRO score of ≥9 points for 3 days or ≥12 points for 2 days.

    Time frame: From first dose of study treatment until last dose of study treatment plus 7 days, up to a maximum duration of 99 days

  15. Annualized Rate of EXACT-PRO-defined Exacerbations

    The Exacerbations of COPD Tool-Patient Reported Outcome (EXACT-PRO) is a validated 14-item electronic questionnaire designed to detect the frequency, severity, and duration of exacerbations in participants with COPD. Minimum score is 0 and Maximum score is 40 (higher scores indicate worsening indicative of an exacerbation). EXACT-PRO-defined exacerbations are defined as a persistent increase from baseline in total EXACT-PRO score of ≥9 points for 3 days or ≥12 points for 2 days. Annualized rate of exacerbations was analyzed using a generalized linear model assuming a negative binomial distribution.

    Time frame: From first dose of study treatment until last dose of study treatment plus 7 days, up to a maximum duration of 99 days

  16. Change From Baseline in Airway Wall and Lumen

    To assess the effect of QBW251 compared to placebo after 12 weeks of treatment on airway structure and function, measured by High Resolution Computed Tomography (HRCT).

    Time frame: Baseline, week 12.

  17. Change From Baseline in Percent Global and Regional Air Trapping After 12 Weeks of Treatment

    To assess the effect of QBW251 compared to placebo after 12 weeks of treatment on airway structure and functions, measured by High Resolution Computed Tomography (HRCT). Air trapping is defined as the percentage of lung voxels with mean attenuation below -856 Hounsfield units (HU).

    Time frame: Baseline, week 12.

07

Results

Posted Oct 4, 2023

Participant flow

Participants took part in 12 investigative sites in 4 countries.

Participant flow — Overall Study
MilestoneQBW251 300mgPlacebo
Started2628
Completed2428
Not completed20
Withdrew: Adverse event10
Withdrew: Participant decision10

Outcome measures

PrimaryChange From Baseline in Fibrinogen Plasma Concentrations After 12 Weeks of Treatment

To assess the effect of QBW251 compared to placebo after 12 weeks of treatment on fibrinogen. The least-squares means for change from baseline in fibrinogen plasma concentrations after 12 weeks visits for each individual dose group were obtained from a linear mixed effects model for repeated measures (MMRM). A MMRM was fitted to the changes from baseline in fibrinogen for all time points until Day 84. A decrease in fibrinogen plasma concentration indicates improvement.

Time frame:
Baseline, week 12.
Reported as:
Least squares mean · g/L
Change From Baseline in Fibrinogen Plasma Concentrations After 12 Weeks of Treatment
g/LQBW251 300mgPlacebo
Change From Baseline in Fibrinogen Plasma Concentrations After 12 Weeks of Treatment-0.086 ± 0.13740.117 ± 0.1365
Statistical analysis
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.298 · Least squares mean: -0.203 · 80% CI -0.524 to 0.119Treatment difference (QBW251-placebo)
SecondaryChange From Baseline in Total Bacteria Load of log10 Colony Forming Units (CFU) After 12 Weeks of Treatment

Change from baseline in total bacteria load of colony forming units of potentially pathogenic microorganisms in sputum. A decrease in airway bacterial colonization as detected in the sputum is considered improvement.

Time frame:
Baseline, week 12.
Reported as:
Least squares mean · log10 CFU/mL
Change From Baseline in Total Bacteria Load of log10 Colony Forming Units (CFU) After 12 Weeks of Treatment
log10 CFU/mLQBW251 300mgPlacebo
Change From Baseline in Total Bacteria Load of log10 Colony Forming Units (CFU) After 12 Weeks of Treatment-0.2 ± 0.300.0 ± 0.32
Statistical analysis
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.651 · Least squares mean: -0.2 · 80% CI -0.9 to 0.5Treatment difference (QBW251-placebo)
SecondaryChange From Baseline in COPD Assessment Test (CAT) Questionnaire After 12 Weeks of Treatment

The COPD assessment test (CAT) is a short instrument which was used to quantify the symptom burden of COPD and disease severity of participants in this study. The CAT consists of 8 items, each presented as a semantic 6-point differential scale (0-5), providing a total range from 0 to 40. A higher score indicates a worse health status.

Time frame:
Baseline, week 12.
Reported as:
Least squares mean · Score on a scale
Change From Baseline in COPD Assessment Test (CAT) Questionnaire After 12 Weeks of Treatment
Score on a scaleQBW251 300mgPlacebo
Change From Baseline in COPD Assessment Test (CAT) Questionnaire After 12 Weeks of Treatment-3.55 ± 0.947-2.16 ± 0.874
Statistical analysis
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.288 · Least squares mean: -1.39 · 80% CI -3.55 to 0.78Treatment difference (QBW251-placebo)
SecondaryChange From Baseline in Euro Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire After 12 Weeks of Treatment

The EQ-5D-3L questionnaire is a general health status and health utility measure which captures 5 dimensions of health state: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and visual analog has a scale 0 to 100 (0=worst imaginable health state, 100=best imaginable health state).

Time frame:
Baseline, week 12.
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Euro Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire After 12 Weeks of Treatment
Score on a scaleQBW251 300mgPlacebo
Change From Baseline in Euro Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire After 12 Weeks of Treatment7.63 ± 3.1163.43 ± 2.854
Statistical analysis
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.338 · Least squares mean: 4.20 · 80% CI -3.09 to 11.48Treatment difference (QBW251-placebo)
SecondaryChange From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total and Domain Scores After 12 Weeks of Treatment

The St. George's Respiratory questionnaire (SGRQ) was used to provide the health status measurements. The SGRQ contains 50 items divided into two parts covering three aspects of health related to COPD: Part I covers "Symptoms", Part II covers "Activity" and "Impacts". A score is calculated for each of these three subscales including the "Total" score. In each case the lowest possible value is zero and the highest 100. Higher values correspond to greater impairment of health status.

Time frame:
Baseline, week 12.
Reported as:
Least squares mean · Score on a scale
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total and Domain Scores After 12 Weeks of Treatment
Score on a scaleQBW251 300mgPlacebo
Week 12- total score-2.99 ± 2.297-2.17 ± 2.111
Week 12- Symptoms score-0.98 ± 3.052-6.73 ± 2.806
Week 12- Activity score-1.96 ± 2.388-1.35 ± 2.194
Week 12- Impact score-3.72 ± 2.944-1.65 ± 2.705
Statistical analysis
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.795 · Least squares mean: -0.82 · 80% CI -6.05 to 4.42Treatment difference (QBW251-placebo)
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.170 · Least squares mean: 5.75 · 80% CI -1.16 to 12.66Treatment difference (QBW251-placebo)
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.851 · Least squares mean: -0.61 · 80% CI -6.02 to 4.80Treatment difference (QBW251-placebo)
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.610 · Least squares mean: -2.07 · 80% CI -8.78 to 4.65Treatment difference (QBW251-placebo)
SecondaryChange From Baseline in Cough and Sputum Assessment Questionnaire (CASA-Q) After 12 Weeks of Treatment

The CASA-Q is a validated questionnaire used to measure cough and sputum production, and their impact in patients with COPD and/or chronic bronchitis. There are only domain scores and no overall score. The scores in each domain range from 0 to 100, with lower scores indicating more severe symptoms or a higher impact.

Time frame:
Baseline, week 12.
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Cough and Sputum Assessment Questionnaire (CASA-Q) After 12 Weeks of Treatment
Score on a scaleQBW251 300mgPlacebo
Week 12 - cough symptom score4.36 ± 3.3394.11 ± 3.083
Week 12 - sputum symptom score5.00 ± 3.4010.78 ± 3.121
Week 12 - cough impact score4.64 ± 2.9362.60 ± 2.697
Week 12 - sputum impact score3.22 ± 3.2982.28 ± 3.017
Statistical analysis
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.956 · Least squares mean: 0.25 · 80% CI -7.30 to 7.80Treatment difference (QBW251-placebo)
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.369 · Least squares mean: 4.22 · 80% CI -3.55 to 11.99Treatment difference (QBW251-placebo)
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.613 · Least squares mean: 2.03 · 80% CI -4.61 to 8.68Treatment difference (QBW251-placebo)
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.835 · Least squares mean: 0.94 · 80% CI -6.58 to 8.47Treatment difference (QBW251-placebo)
SecondaryPre-dose Trough Concentration (Ctrough) of QBW251

Pharmacokinetic blood samples were collected and evaluated in all participants exposed to QBW251. QBW251 was analyzed by a validated Liquid Chromatography with tandem Mass Spectrometry. Concentration below the lower limit of quantification (LLOQ) was reported as zero.

Time frame:
Day 1, Day 28, Day 56 and Day 84
Reported as:
Mean · ng/mL
Pre-dose Trough Concentration (Ctrough) of QBW251
ng/mLQBW251 300mg
Day 10.00 ± 0.00
Day 28526 ± 735
Day 56489 ± 540
Day 84567 ± 883
SecondaryChange From Baseline in Trough FEV1 After 12 Weeks of Treatment

FEV1 (forced expiratory volume in one second) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The least-squares means for change from baseline in FEV1 to assess the effect of QBW251 compared to placebo after 12 weeks were obtained from a linear mixed effects model for repeated measures (MMRM). A positive change from baseline in pre-dose FEV1 is considered a favourable outcome.

Time frame:
Baseline, week 12.
Reported as:
Least squares mean · liters (L)
Change From Baseline in Trough FEV1 After 12 Weeks of Treatment
liters (L)QBW251 300mgPlacebo
Change From Baseline in Trough FEV1 After 12 Weeks of Treatment0.0 ± 0.03-0.1 ± 0.03
Statistical analysis
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.335 · Least squares mean: 0.0 · 80% CI 0.0 to 0.1Treatment difference (QBW251-placebo)
SecondaryChange From Baseline in FVC After 12 Weeks of Treatment

To assess the effect of QBW251 compared to placebo after 12 weeks of treatment on spirometry (Forced Vital Capacity). Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.

Time frame:
Baseline, week 12
Reported as:
Least squares mean · liters (L)
Change From Baseline in FVC After 12 Weeks of Treatment
liters (L)QBW251 300mgPlacebo
Change From Baseline in FVC After 12 Weeks of Treatment-0.1 ± 0.05-0.1 ± 0.05
Statistical analysis
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.645 · Least squares mean: 0.0 · 80% CI -0.1 to 0.1Treatment difference (QBW251-placebo)
SecondaryChange From Baseline in FEV1/FVC After 12 Weeks of Treatment

To assess the effect of QBW251 compared to placebo after 12 weeks of treatment on spirometry. FEV1/FVC is the percent of a person's vital capacity that they are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC).

Time frame:
Baseline, week 12.
Reported as:
Least squares mean · percent
Change From Baseline in FEV1/FVC After 12 Weeks of Treatment
percentQBW251 300mgPlacebo
Change From Baseline in FEV1/FVC After 12 Weeks of Treatment1.7 ± 0.58-0.3 ± 0.55
Statistical analysis
  • QBW251 300mg vs Placebo · Mixed effects Model for Repeated Measure · p = 0.010 · Least squares mean: 2.1 · 80% CI 0.8 to 3.4Treatment difference (QBW251-placebo)
SecondaryMaximum Observed Plasma Concentrations (Cmax) of QBW251 in a Subset of Patient Population

Cmax is the maximum (peak) observed plasma concentration of QBW251 after dose administration. QBW251 was analyzed by a validated Liquid Chromatography with tandem Mass Spectrometry. Concentration below the lower limit of quantification was reported as zero. Serial plasma PK concentrations were sampled on Day 1 and Day 28 up to 8 hours post dose in a subset of the patient population.

Time frame:
Pre dose, Post dose (1, 2, 3, 4, 6, and 8 hours) at Day 1 and Day 28.
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentrations (Cmax) of QBW251 in a Subset of Patient Population
ng/mLQBW251 300mg
Day 11000 ± 608
Day 281580 ± 866
SecondaryMaximum Observed Plasma Concentrations (Cmax) of QBW251

Cmax is the maximum (peak) observed plasma concentration of QBW251 after dose administration. QBW251 was analyzed by a validated Liquid Chromatography with tandem Mass Spectrometry. Concentration below the lower limit of quantification was reported as zero. On Day 56 and Day 84 pre-dose and 3 hour post dose sparse samples were collected from all participants.

Time frame:
Post-dose (3 hours) at Day 56 and Day 84.
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentrations (Cmax) of QBW251
ng/mLQBW251 300mg
Day 56903 ± 648
Day 84997 ± 497
SecondaryArea Under Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) of QBW251

Pharmacokinetic blood samples were collected and evaluated in all participants exposed to QBW251. QBW251 was analyzed by a validated Liquid Chromatography with tandem Mass Spectrometry. Concentration below the lower limit of quantification was reported as zero. AUClast is the area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (tlast) of QBW251.

Time frame:
Pre dose, Post dose (1, 2, 3, 4, 6, and 8 hours) at Day 1 and Day 28
Reported as:
Mean · h*ng/mL
Area Under Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) of QBW251
h*ng/mLQBW251 300mg
Day 14290 ± 3630
Day 287320 ± 5950
SecondaryOn-treatment Analysis of Time to First COPD Exacerbation Using Cox Regression Model

To assess the effect of QBW251 compared to placebo after 12 weeks of treatment on COPD exacerbations, exacerbations defined by EXACT-PRO questionnaire. The protocol defined that the time-to-event analyses were to be carried out only upon sufficient number of exacerbation events occur during the study to estimate the median in either of the treatment groups.

Time frame:
Baseline, week 12.

No measurements were reported for this outcome.

SecondaryProportion of Patients (Percentage) With Exacerbations

The EXACT-PRO is a validated 14-item electronic questionnaire designed to detect the frequency, severity, and duration of exacerbations in participants with COPD. Minimum score is 0 and Maximum score is 40 (higher scores indicate worsening indicative of an exacerbation). EXACT-PRO-defined exacerbations are defined as a persistent increase from baseline in total EXACT-PRO score of ≥9 points for 3 days or ≥12 points for 2 days.

Time frame:
From first dose of study treatment until last dose of study treatment plus 7 days, up to a maximum duration of 99 days
Reported as:
Count of participants · Participants
Proportion of Patients (Percentage) With Exacerbations
ParticipantsQBW251 300mgPlacebo
Proportion of Patients (Percentage) With Exacerbations33
SecondaryAnnualized Rate of EXACT-PRO-defined Exacerbations

The Exacerbations of COPD Tool-Patient Reported Outcome (EXACT-PRO) is a validated 14-item electronic questionnaire designed to detect the frequency, severity, and duration of exacerbations in participants with COPD. Minimum score is 0 and Maximum score is 40 (higher scores indicate worsening indicative of an exacerbation). EXACT-PRO-defined exacerbations are defined as a persistent increase from baseline in total EXACT-PRO score of ≥9 points for 3 days or ≥12 points for 2 days. Annualized rate of exacerbations was analyzed using a generalized linear model assuming a negative binomial distribution.

Time frame:
From first dose of study treatment until last dose of study treatment plus 7 days, up to a maximum duration of 99 days
Reported as:
Number · exacerbations per participant per year
Annualized Rate of EXACT-PRO-defined Exacerbations
exacerbations per participant per yearQBW251 300mgPlacebo
Annualized Rate of EXACT-PRO-defined Exacerbations1.22 (0.74 to 2.03)1.01 (0.61 to 1.67)
SecondaryChange From Baseline in Airway Wall and Lumen

To assess the effect of QBW251 compared to placebo after 12 weeks of treatment on airway structure and function, measured by High Resolution Computed Tomography (HRCT).

Time frame:
Baseline, week 12.
Reported as:
Mean · mm
Change From Baseline in Airway Wall and Lumen
mmQBW251 300mgPlacebo
Lung, Left, Inferior Lobe, Posterior Basal Segment0.01 ± 0.2010.02 ± 0.155
Lung, Left, Superior Lobe, Apical Segment-0.01 ± 0.1500.06 ± 0.134
Lung, Right, Inferior Lobe, Posterior Basal Segment0.08 ± 0.378-0.03 ± 0.149
Lung, Right, Middle Lobe, Lateral Segment0.00 ± 0.145-0.06 ± 0.105
Lung, Right, Superior Lobe, Apical Segment-0.02 ± 0.1280.02 ± 0.092
SecondaryChange From Baseline in Percent Global and Regional Air Trapping After 12 Weeks of Treatment

To assess the effect of QBW251 compared to placebo after 12 weeks of treatment on airway structure and functions, measured by High Resolution Computed Tomography (HRCT). Air trapping is defined as the percentage of lung voxels with mean attenuation below -856 Hounsfield units (HU).

Time frame:
Baseline, week 12.
Reported as:
Mean · percent air trapping
Change From Baseline in Percent Global and Regional Air Trapping After 12 Weeks of Treatment
percent air trappingQBW251 300mgPlacebo
Lung-3.53 ± 7.534-0.95 ± 7.733
Lung, Left-3.93 ± 7.176-0.89 ± 7.248
Lung, Left Lower Lobe-4.27 ± 9.708-1.55 ± 7.486
Lung, Left Upper Lobe-3.83 ± 7.220-0.78 ± 7.910
Lung, Right-3.24 ± 8.280-0.98 ± 9.032
Lung, Right Lower Lobe-3.57 ± 9.896-1.90 ± 11.666
Lung, Right Middle Lobe-1.98 ± 10.362-0.80 ± 8.480
Lung, Right Upper Lobe-2.09 ± 8.5000.27 ± 8.934
Thirds, Left Lower-5.40 ± 10.613-1.90 ± 8.111
Thirds, Left Middle-3.56 ± 6.803-0.76 ± 6.659
Thirds, Left Upper-2.84 ± 7.597-0.11 ± 9.272
Thirds, Right Lower-4.52 ± 8.545-1.70 ± 10.890
Thirds, Right Middle-3.28 ± 9.116-1.09 ± 8.218
Thirds, Right Upper-1.84 ± 8.9560.18 ± 10.107

Adverse events

Collected over Adverse events were reported from first dose of study treatment until last dose of study treatment plus 7 days, up to a maximum duration of 99 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
QBW251 300 mg b.i.d0/26 (0%)2/26 (7.7%)12/26 (46.2%)
Placebo0/28 (0%)0/28 (0%)5/28 (17.9%)
Total0/54 (0%)2/54 (3.7%)17/54 (31.5%)
Most frequent serious events
Most frequent serious events
EventQBW251 300 mg b.i.dPlaceboTotal
Arrhythmia supraventricularCardiac disorders1/260/281/54
PneumoniaInfections and infestations1/260/281/54
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/260/281/54
Most frequent other events
Most frequent other events
EventQBW251 300 mg b.i.dPlaceboTotal
DiarrhoeaGastrointestinal disorders4/260/284/54
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders4/263/287/54
NasopharyngitisInfections and infestations3/261/284/54
Pulmonary massRespiratory, thoracic and mediastinal disorders3/261/284/54
COVID-19Infections and infestations1/262/283/54

Baseline characteristics

Age, Continuous
Age, Continuous(years)QBW251 300mgPlaceboTotal
Mean65.7 ± 7.1367.3 ± 8.3766.5 ± 7.77
Sex: Female, Male
Sex: Female, Male(Participants)QBW251 300mgPlaceboTotal
Female161127
Male101727
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)QBW251 300mgPlaceboTotal
White262854
08

Study locations

12 sites
  • Novartis Investigative Site
    Feldbach, 8330, Austria
  • Novartis Investigative Site
    Heidelberg, Baden-Württemberg 69126, Germany
  • Novartis Investigative Site
    Berlin, 10119, Germany
  • Novartis Investigative Site
    Berlin, 10969, Germany
  • Novartis Investigative Site
    Frankfurt, 60596, Germany
  • Novartis Investigative Site
    Mainz, 55128, Germany
  • Novartis Investigative Site
    Witten, 58452, Germany
  • Novartis Investigative Site
    Basel, 4031, Switzerland
  • Novartis Investigative Site
    St Gallen, 9007, Switzerland
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
  • Novartis Investigative Site
    Bradford, West Yorkshire BD9 6RJ, United Kingdom
  • Novartis Investigative Site
    London, SW3 6HP, United Kingdom
09

References and documents

Study documents

  • Study protocol · Aug 25, 2021
  • Statistical analysis plan · Dec 23, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04268823
Lead sponsor
Novartis Pharmaceuticals
Responsible party
Sponsor
First posted
Feb 13, 2020
Start date
Sep 10, 2020
Primary completion
Sep 13, 2022
Completion
Sep 20, 2022
Results posted
Oct 4, 2023
Last update
Jun 20, 2024

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lung Diseases→

Other studies from this sponsor

Novartis Pharmaceuticals

Start the discussion